Juvenile Idiopathic Arthritis in Children in Estonia.

March 23, 2020 updated by: Chris Pruunsild, University of Tartu

Juvenile Idiopathic Arthritis in Children in Estonia - an Epidemiological and Clinical Investigation.

Aims of the study:

  • to study the incidence rate of juvenile idiopathic arthritis (JIA) and it's clinical subtypes in Estonia for the years 1998-2000;
  • to examine the course and short-term clinical outcome of JIA.

Method: a prospective population-based study carried on in 14 counties of Estonia

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

162

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 month to 15 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

During years 1998-2000, 162 newly-diagnosed juvenile idiopathic arthritis cases from 14 counties of Estonia, were included to the study, among them 76 boys and 86 girls.

Description

Inclusion Criteria:

  • The International League of Associations for Rheumatology (ILAR) criteria for juvenile idiopathic arthritis
  • children aged 0-15 years who had arthritis of an unknown cause for at least six weeks with an onset of the disease during the study period

Exclusion Criteria:

  • Children with infectious arthritis, postinfectious arthritis, traumatic arthritis and systemic connective tissue diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Subsequent new juvenile arthritis cases
During years 1998-2000, all new subsequent cases of juvenile idiopathic arthritis diagnosed in Estonia were included in the study group.
Other: Blood collecting for storage of samples

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Mean annual incidence rate of juvenile idiopathic arthritis in Estonia during years 1998-2000.
Time Frame: 3 years
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Tartu

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 1998

Primary Completion (Actual)

December 1, 2000

Study Completion (Actual)

December 1, 2002

Study Registration Dates

First Submitted

July 16, 2013

First Submitted That Met QC Criteria

July 18, 2013

First Posted (Estimate)

July 23, 2013

Study Record Updates

Last Update Posted (Actual)

March 25, 2020

Last Update Submitted That Met QC Criteria

March 23, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TARLA 0475;DARLA 0500

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Epidemiology

Clinical Trials on Blood collecting for storage of samples

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe